Abstract
The high incidence of bone defect cases necessitates a rapid development of cost-effective bone tissue engineering approaches. Bone growth factors such as bone morphogenetic protein-2 (BMP-2) play a vital role in bone tissue engineering. The osteoinductive efficacy of BMP-2 and other osteogenic growth factors is highly dependent on their dose and delivery mode. Slow and sustained delivery of a low dose of BMP-2 promotes bone defect healing. However, the burst release of a high dose of BMP-2 not only fails to promote bone healing but also causes adverse local and systemic effects. The biomimetic calcium phosphate (BioCaP) coating technique guarantees a slow, gradual, and local release of BMP-2 to mimic its natural release from the bone matrix under physiological conditions. Therefore, BioCaP coatings have long been regarded as a promising drug carrier for growth factors. In this mini-review, we give a brief introduction to BioCaP coatings regarding their preparation techniques, physicochemical properties, potential as a drug carrier, ability to suppress foreign body reactivity, and their preclinical application in ectopic and orthotopic models. Finally, the current challenges and future prospects of BioCaP coatings are discussed.
Original language | English |
---|---|
Article number | 1118 |
Pages (from-to) | 1-19 |
Number of pages | 19 |
Journal | Coatings |
Volume | 10 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2020 |
Funding
Funding: This work was funded by the National Natural Science Foundation of China [grant number: 81670960], Fundamental Research Funds for the Central Universities [grant number 0214-14380489]; the Jiangsu Natural Science Funds [grant number SBK2020041847] and the Nanjing Scientific Innovation Project for Overseas Researchers [grant number 2019-C-173].
Funders | Funder number |
---|---|
Jiangsu Natural Science Funds | SBK2020041847 |
Nanjing Scientific Innovation Project for Overseas Researchers | 2019-C-173 |
National Natural Science Foundation of China | 81670960 |
Fundamental Research Funds for the Central Universities | 0214-14380489 |